Belépés

NCT07377136Fut, nem toboroz

Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating.

Studie Vlivu Urolithinu A na Populaci s BI vyšším neý 30 při výživové Restrikci

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. okt. 26.

Rövid összefoglaló (regiszter, angolul)

Purpose. This study will test whether daily Urolithin A (500 mg) for 6 months helps adults with obesity lose weight while preserving functional muscle mass and improving markers of mitochondrial health, inflammation, and metabolism. All participants receive the same structured lifestyle program (nutrition and sleep guidance); half will receive Urolithin A and half a matching placebo. Background. Weight loss can improve health but may also reduce skeletal muscle, especially in people with obesity. Aging and obesity are both linked to mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress, and low-grade inflammation. Urolithin A is a gut-derived, diet-related compound that promotes mitophagy and may support muscle function and metabolic health. Design. Single-center, randomized, placebo-controlled, parallel-group trial. About 100 adults aged 30-60 years with BMI \>30 kg/m² and elevated visceral adiposity will be enrolled and randomized in a 1:1 ratio (stratified by sex and age ≤45 vs ≥45 years). Blinding will include participants, study staff, and assessors. Intervention. Urolithin A 500 mg orally once daily vs matching placebo, for 24 weeks. A standardized lifestyle program for all participants: individualized energy restriction with higher protein intake, reduced carbohydrates, and time-restricted eating (11-hour eating window / 13-hour overnight fast); plus structured sleep-hygiene recommendations and light daily activity guidance. No other dietary supplements are allowed during the study. Main assessments. At baseline and regularly during the study, participants will undergo: Body composition by bioimpedance (InBody), including skeletal muscle and visceral fat indices. Muscle function (handgrip dynamometry; 30-second chair-stand). Cardiometabolic and inflammatory biomarkers from blood (standard biochemistry, lipids, glucose/HbA1c, CRP; exploratory cytokines/adipokines). Mitochondrial/aging biomarkers, including DNA-based epigenetic aging measures. Cardiovascular/ANS function (heart-rate variability and vascular indices; MaxPulse Medicore). Questionnaires on sleep quality, physical activity, and weight-management self-efficacy. Visits and duration. 6-month participation with baseline, 3-weekly check-ins, and a final visit for repeat testing and blood sampling. Outcomes. The study focuses on safety and on whether Urolithin A, compared with placebo, helps preserve functional muscle mass and improves mitochondrial, inflammatory, and metabolic biomarkers during weight loss. Who can join. Adults 30-60 years with obesity and higher visceral fat who are willing to follow the lifestyle program. Key medical exclusions (e.g., diabetes, active autoimmune disease, pregnancy) and supplement restrictions apply; full criteria are provided in the Eligibility section. Potential benefits and risks. Participants may benefit from weight loss support and close monitoring. Risks include blood draw discomfort and potential, usually mild, supplement-related side effects. Safety will be monitored throughout. Location and sponsor. The study is conducted at Charles University, Faculty of Medicine in Hradec Králové (Czech Republic) under the Department of Preventive Medicine.

Állapot (regiszter)
Fut, nem toboroz
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
102 (tényleges)
Első benyújtás
2025. szept. 29.
Kezdés
2025. okt. 8.
Elsődleges befejezés
2026. aug. 14.
Fő szponzor
Charles University, Czech Republic
Betegségek
Elhízás
NCT-szám
NCT07377136

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Bevont résztvevők: 102
  • 2025. okt. 8. és az elsődleges befejezés (2026. aug. 14.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Dyslipidemia treated with statins

Más betegség

  • Known thyroid disease (untreated/unstable hypothyroidism or hyperthyroidism)
  • Autoimmune disease, including psoriasis
  • Inflammatory bowel disease or other chronic inflammatory GI disorders (e.g., Crohn's disease, celiac disease)
  • Active malignant disease
  • Cognitive impairment or neurodegenerative disease that may affect consent or adherence
  • Severe psychiatric disorder that would preclude participation (e.g., severe major depression) or unstable depression/medication changes within the past 3 months
  • Uncontrolled comorbidity or decompensated chronic disease (e.g., uncontrolled hypertension; systolic ≥175 mmHg at screening)
  • Severe or limiting musculoskeletal condition preventing participation in assessments or the lifestyle program
  • Known allergy/intolerance to Urolithin A or capsule excipients
  • Any condition that, in the investigator's judgment, makes participation unsafe or could compromise data integrity

Laborértékek

  • Type 2 diabetes mellitus (diagnosed or on glucose-lowering therapy)

Egyéb

  • Pregnancy, lactation, or planned pregnancy during the study period
  • Use of non-study dietary supplements (vitamins, herbal/nutraceutical products) that the participant is unwilling or unable to discontinue from baseline through end of study

Kiket keres a vizsgálat

  • Age 30-60 years (inclusive) at screening
  • BMI \> 30 kg/m² at screening
  • Visceral fat level ≥ 12 by segmental bioimpedance (InBody) at screening
  • Able and willing to follow the standardized lifestyle program (individualized energy restriction with higher protein, reduced carbohydrates, time-restricted eating 11:13) and sleep-hygiene guidance for 24 weeks
  • Willing to attend baseline and \~3-weekly follow-ups; undergo blood draws, bioimpedance, MaxPulse testing, and muscle strength/endurance tests; and complete questionnaires (WEL, PSQI, GPAQ)
  • Medication stability: chronic medications (e.g., treated hypertension, antidepressants) stable for ≥3 months before baseline; only clinically necessary changes allowed during the study
  • Permitted conditions/therapies (if stable): common allergies/atopic eczema; food intolerances; contraception and menopausal hormone therapy
  • Women of childbearing potential: negative pregnancy test at baseline; agreement to use highly effective contraception during the study and for 4 weeks after last dose; not breastfeeding
  • Able to provide written informed consent

Életkor a regiszterben: 30 év – 60 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Charles University, Faculty of Medicine in Hradec Kralove
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát
Hradec KrálovéCsehországIsmeretlen állapot

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.